Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — PCR London Valves 2022
13 slides from Anteris Technologies Global's conference presentation, Dec 8, 2022
Slide 1: DurAVR Transcatheter Aortic Valve First-in-Human Study: Impact of Novel Leaflet Design
DurAVR™ Transcatheter Aortic Valve First-in-Human Study: Impact of Novel Leaflet Design Christopher U. Meduri, MD MPH Karolinska University Hospital, Stockholm (Sweden)
Slide 2: Potential conflicts of interest
Potential conflicts of interest I have the following potential conflicts of interest to report: CMO: Anteris Technologies Receipt of grants / research support: Boston Scientific Receipt of honoraria or consultation fees: Abbott, Alleviant, Boston Scientific, Cardiovalve, VDyne, XDot PCRLondonValve
Slide 3: TAVI Consists of Compromises
TAVI Consists of Compromises Current TAVR platforms impair optimal lifetime management strategies Balloon Expandable Advantages Self Expandable Advantages ✓ Short frame height ✓ Optimal Haemodynamics* ✓ Ease of use ✓ Commissure alignment DurAVR™ THV ✓ Native Leaflet Design ✓ Advanced Acellular Tissu
Slide 4: DurAVR Shaped to Perform like Native Aortic Valve
DurAVR™ Shaped to Perform like Native Aortic Valve A valve designed To Restore near-normal hemodynamic function For Better coaptation and less leaflet stress NEAR-NORMAL IMPROVED HEMODYNAMICS CORONARY ACCESS Unique single-piece valve design Large, open cell geometry for larger EOA and lower gradient
Slide 5: DurAVR FIH Study Design & Baseline Characteristics
DurAVR™ FIH Study Design & Baseline Characteristics Design Baseline characteristics n = 13 Prospective, non-randomised, single-arm, Age (years) 73.92 ± 6.4 single-centre Gender (female) 77% STS Prom (%) 2.34 ± 1.07 Purpose Area-derived annulus diameter (mm) 22.95 ± 1.09 Evaluate the safety and feasi
Slide 6: Procedural Results
Procedural Results 100% Procedural Success ✓ No moderate or severe paravalvular leak ✓ One mild/moderate central AR (early case before valve sizing optimization Rotation for Alignment Deployment Mean coaptation length 8.3 mm PCRLondonValves.com
Slide 7: Clinical Outcomes
Clinical Outcomes ✓ No deaths ✓ No stroke ✓ No minor or major bleeding ✓ No reoperation or reintervention ✓ No myocardial infarction ✓ No device-related complications ✓ One access site complication (resolved on POD 1) ✓ One new pacemaker in a patient with baseline RBBB and LAFB (POD 6) AR = Aortic R
Slide 8: Unique Native Like Leaflets Result in Native Like Function
Unique Native Like Leaflets Result in Native Like Function Restores Normal Aortic Flow Dynamics 30 Days Echo 30 Days MDCT Consistent laminar flow throughout valve Native valve-like leaflet function PCRLondonValves.com
Slide 9: Exceptional Hemodynamic Results at 30 Days in BE Platform
Exceptional Hemodynamic Results at 30 Days in BE Platform Mean annulus size: 22.95 mm EOA (cm2) EOAi (cm2/m2) 2.5 1.5 1.15 2.00 2.0 1.0 1.5 1.0 0.50 0.5 0.27 0.5 0.0 0.0 Baseline 30 Days Baseline 30 Days MPG (mmHg) DVI 70 0.70 49.25 0.53 35 0.35 0.20 9.02 0 0.00 Baseline 30 Days Baseline 30 Days EOA
Slide 10: DurAVR: First AVR Shown to Restore Normal Aortic Flow
DurAVR™: First AVR Shown to Restore Normal Aortic Flow Healthy Aortic Valve Post DurAVR THV FD = 10% FD = 14% FRR = 1% FRR = 4% (n=5) (n=5) Normal Valve vs DurAVR™: No significant difference in flow (p > 0.05) Impaired Aortic Flow Severe AS Edwards Sapien 3 Medtronic Evolut R CEP Magna Ease FD = 46%
Slide 11: DurAVR: Challenging the AS Treatment Paradigm
DurAVR™: Challenging the AS Treatment Paradigm Provides the benefits of balloon expanding and self-expanding valve in one platform Restores normal function through unique single-piece native shaped valve FIH study shows remarkable safety and hemodynamic performance (EOA = 2.0 cm2 with mean annulus o
Slide 12: Anteris DurAVR THV System
Anteris DurAVR™ THV System Designed to Last Longer & Work Better For further information * * * PCRLondonValves.com
Slide 13: PCRonline.com
PCR PCRonline.com